Novartis : Sales down but good work in terms of the margin
>A slowdown expected due to COVID-19 - The company reported Q2 sales below expectations (-3.7% vs the consensus) but in line in terms of its core EPS. Group sales declined by -1% cc in Q2 (pharma +1% cc/ Sandoz -9% cc), negatively impacted by the purchases made in Q1 in anticipation of Q2 which were broadly not renewed in Q2. Regarding the pharma business, Cosentyx was up +12% cc, nonetheless hit by dermatology and rheumatology practices but offset by an increase...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.